Fish Oil Triglycerides
Pediatric

  • TRADE NAME: Omegaven (Fresenius Kabi USA)
  • INDICATIONS: indicated as a source of calories and fatty acids in pediatric patients with parenteral nutrition-associated cholestasis
  • FDA APPROVAL DATE: 07/27/2018
  • CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
    None known
  • PREGNANCY: no available data

Risk of Death in Preterm Infants due to Pulmonary Lipid Accumulation; Hypersensitivity Reactions; Risk of Infections, Fat Overload Syndrome, Refeeding Syndrome, and Hypertriglyceridemia; Aluminum Toxicity

See full prescribing information for complete boxed warning

Please login to view the rest of this drug profile.

Page last updated 08/20/2025

Symbol key

Incidence - Help

<1% 1‑5% 5‑10% 10‑15% 15‑20% 20‑30% >30%

Seriousness - Help

Hospitalization possible
Life threatening
Fatal

Warnings in other populations - Help

BreastfeedingBreast feeding

GeriatricGeriatric

PediatricPediatric

Back to top